Safety and Effectiveness of 100 mg/kg/day Deferiprone in Patients with Thalassemia Major: A Two-Year Study

Publisher： Karger

E-ISSN： 1421-9662|114|3|146-149

ISSN： 0001-5792

Source： Acta Haematologica, Vol.114, Iss.3, 2005-10, pp. : 146-149

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β‐thalassemia major: A prospective, single center, open‐label study

By  

PEDIATRIC BLOOD & CANCER (ELECTRONIC), Vol. 62, Iss. 9, 2015-09 ,pp. : 1592-1596

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder*

By Liebowitz Michael R.   Manley Amy L.   Padmanabhan Sudharshan K.   Ganguly Rita   Tummala Raj   Tourian Karen A.  

Current Medical Research and Opinion, Vol. 24, Iss. 7, 2008-07 ,pp. : 1877-1890

Informa Healthcare

Access to resources Recommend Favorite

Deferiprone Chelation Therapy for Thalassemia Major

By  

Acta Haematologica, Vol. 122, Iss. 2-3, 2009-11 ,pp. : 155-164

Karger

Access to resources Recommend Favorite

A TWO‐YEAR COMPARATIVE STUDY OF ATARAXICS IN NEUROPSYCHIATRIC PATIENTS†

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 5, Iss. 4, 1957-04 ,pp. : 421-429

John Wiley & Sons Inc

Access to resources Recommend Favorite

Five-Year Trial of Deferiprone Chelation Therapy in Thalassaemia major Patients

By  

Acta Haematologica, Vol. 112, Iss. 4, 2004-11 ,pp. : 179-183

Karger

Access to resources Recommend Favorite